This was the stock's second consecutive day of gains.

Despite AbbVie’s underperformance relative to the S&P 500 over the past year, Wall Street analysts maintain a moderately ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

Allergan Aesthetics scored a big legal patent infringement win tied to its blockbuster wrinkle-treatment Botox. A federal ...

REGENXBIO to initiate pivotal phase IIb/III clinical trial of surabgene lomparvovec in diabetic retinopathy: Rockville, Maryland Friday, August 8, 2025, 15:00 Hrs [IST] REGENXBIO ...

Ariel’s non-consensus approach seeks to identify undervalued, out-of-favor, franchises that are misunderstood and therefore ...

Gedeon Richter, Hungary’s biggest drugmaker, aims to clinch more deals like its partnership with AbbVie Inc. to expand in the US without being weighed down by import tariffs imposed by President ...

Abbvie's stock rises 4.51% despite looming trade tensions and competitive pressures. Analysts from Morgan Stanley, Raymond ...

North Chicago, Illinois-based AbbVie Inc. has shown a robust performance despite market fluctuations. While the broader ...